Y-90 clivatuzumab tetraxetan

Drug Profile

Y-90 clivatuzumab tetraxetan

Alternative Names: 90Y-clivatuzumab tetraxetan; 90Y-hPAM4; 90y-Hpama4; Clivatuzumab; Clivatuzumab tetraxetan; Clivatuzumab tetraxetan Y-90; Clivatuzumab Y-90; hPAM4-Cide; hPAM4-DOTA; Humanised monoclonal antibody PAM4 Y-90; IMMU-107; Monoclonal antibody PAM4-Y-90; Pan-Cide; Y-90 clivatuzumab; Yttrium-(90Y) clivatuzumab tetraxetan; Yttrium-90 clivatuzumab tetraxetan; Yttrium-90 labelled monoclonal antibody PAM4

Latest Information Update: 16 Mar 2016

Price : $50

At a glance

  • Originator Immunomedics
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pancreatic cancer

Most Recent Events

  • 14 Mar 2016 Immunomedics terminates the PANCRIT-1 phase III trial in Pancreatic cancer in Austria, Belgium, Canada, France, Israel, Poland, Spain and USA
  • 01 Mar 2016 Immunomedics has patent protection for clivatuzumab tetraxetan in Pancreatic cancer in USA
  • 21 Sep 2015 No recent reports on development identified - Phase-I/II for Pancreatic cancer (Combination therapy, First-line therapy) in USA and Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top